AC
KDNY

Aristides Capital’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Aristides Capital’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,794
Closed -$22K – 270
2019
Q4 		$22K Buy
+3,794
New +$20.6K 0.02% 226

Other funds holding KDNY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Aristides Capital's KDNY Position: Q1 2020 in Review

Aristides Capital sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2020, closing a stake of 3,794 shares — an estimated $22K sold.

Aristides Capital first reported a position in KDNY in Q4 2019 and held it in 1 quarter. The position peaked at $22K in Q4 2019. 82 funds tracked by Wall St. Rank hold KDNY as of Q1 2020.

  • Aristides Capital reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Aristides Capital sold 3,794 Chinook Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $22K.
  • Aristides Capital first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Aristides Capital's Chinook Therapeutics, Inc. Common Stock position peaked at $22K in Q4 2019.
  • 82 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Aristides Capital's 13F filing for Q1 2020, filed 15 May 2020.